Literature DB >> 22396794

A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer.

Daniele Campa1, Juan Sainz, Barbara Pardini, Ludmila Vodickova, Alessio Naccarati, Anja Rudolph, Jan Novotny, Asta Försti, Stephan Buch, Witigo von Schönfels, Clemens Schafmayer, Henry Völzke, Michael Hoffmeister, Bernd Frank, Roberto Barale, Kari Hemminki, Jochen Hampe, Jenny Chang-Claude, Hermann Brenner, Pavel Vodicka, Federico Canzian.   

Abstract

ATP Binding Cassette B1 (ABCB1) is a transporter with a broad substrate specificity involved in the elimination of several carcinogens from the gut. Several polymorphic variants within the ABCB1 gene have been reported as modulators of ABCB1-mediated transport. We investigated the impact of ABCB1 genetic variants on colorectal cancer (CRC) risk. A hybrid tagging/functional approach was performed to select 28 single nucleotide polymorphisms (SNPs) that were genotyped in 1,321 Czech subjects, 699 CRC cases and 622 controls. In addition, six potentially functional SNPs were genotyped in 3,662 German subjects, 1,809 cases and 1,853 controls from the DACHS study. We found that three functional SNPs (rs1202168, rs1045642 and rs868755) were associated with CRC risk in the German population. Carriers of the rs1202168_T and rs868755_T alleles had an increased risk for CRC (P(trend) = 0.016 and 0.029, respectively), while individuals bearing the rs1045642_C allele showed a decreased risk of CRC (P(trend) = 0.022). We sought to replicate the most significant results in an independent case-control study of 3,803 subjects, 2,169 cases and 1,634 controls carried out in the North of Germany. None of the SNPs tested were significantly associated with CRC risk in the replication study. In conclusion, in this study of about 8,800 individuals we show that ABCB1 gene polymorphisms play at best a minor role in the susceptibility to CRC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22396794      PMCID: PMC3292569          DOI: 10.1371/journal.pone.0032784

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Colorectal cancer (CRC) is one of the most common cancers diagnosed in Western countries [1], [2] and its etiology involves the interaction of genetic and environmental factors [3], [4], [5], [6], [7], [8], [9], [10], [11]. Although the biological processes connecting lifestyle characteristics and colorectal carcinogenesis remain unclear, association studies analyzing the influence of dietary factors have evidenced that, at least in part, CRC arises as a consequence of exposure to xenobiotics taken up with food [6], [12]. ATP-binding cassette (ABC) is one of the largest families of active efflux transporters that are located mainly in tissues acting as a barrier or having an excretory function. ABC transporters are highly expressed in the apical membrane of enterocytes where they mediate the efflux of a wide variety of endogenous substrates (including sugars, amino acids, nucleotides, steroids, inorganic ions) into the gut lumen. In addition, most of the ABC transporters play a role in cell defense against environmental attacks generated by xenobiotics [13]. ABCB1 expression in the human intestine increases from proximal to distal, resulting in the highest expression levels in the colon [14], where it is involved in the excretion of several carcinogens from the gut into the intestinal lumen [15]. In addition, it has been demonstrated that ABCB1 is responsible for the efflux of cooked-food mutagens [16], several tobacco-related carcinogens [17], [18], [19], as well as a broad spectrum of drugs [20], [21], [22], [23]. The expression and activity of the ABCB1 transporter may differ between individuals, due to either genetic polymorphisms or pathological conditions [24] and, as a result, this might be reflected in differences in the bioavailability of different toxins, carcinogens and drugs [5]. Over the last decades, this hypothesis has led to a proliferation of in vitro reports examining the functionality of ABCB1 gene polymorphisms and the investigation on their potential role in many diseases and cancers [4], [25], [26], [27], [28], [29], [30], [31]. Functional polymorphic variants of ABCB1 have been reported in the Caucasian population. For example Hoffmeyer and collaborators reported that the C3435T variant (rs1045642) results in a reduced activity and expression of the protein in the duodenum [23]. Likewise, several studies have also focused on the association between polymorphic variants of ABC multidrug transporters and exposure to anticancer drugs [21], [22]. Despite numerous association studies addressing the effect of ABCB1 variants and CRC [30], [31], [32], [33], [34], limited data are available, as most of these association studies have analyzed a reduced number of genetic markers or have been performed in a relatively small population. The aim of the present work was to ascertain if genetic variants within the ABCB1 gene influence the risk of CRC, with particular attention to the role of putatively functional variants that have previously been shown to be associated with cancer risk [24], [30], [32], [33].

Materials and Methods

Ethics statement

All participants signed an informed written consent. The study was approved by the ethical review boards of the institutions responsible for subject recruitment in each of the recruitment centres. The ethical committees were the following: Ethics Committee of the Institute of Experimental Medicine, Prague, Czech Republic. The DACHS study was approved by the ethics committees of the Medical Faculty at the University of Heidelberg and of the Medical Chambers of Baden-Württemberg and Rhineland-Palatinate. The North German Study (Kiel) was approved by the ethics committees of the Medical Faculty at the Christian-Albrechts University of Kiel and Mecklenburg- West Pomerania (Study of Health In Pomerania).

Study populations

In this study three populations of Caucasian origin (one from the Czech Republic and two from Germany) were investigated, including a total of 8786 subjects. All the populations were previously described in detail [35]. Briefly, the first case-control study comprises 1321 subjects, 699 CRC cases and 622 controls from the Czech Republic [36]. All participants were recruited from six oncological and five gastroenterological departments, all over the Czech Republic. The study was based on incident cases with positive colonoscopic results for malignancy and with histologically confirmed colon or rectal carcinoma. Controls were defined as subjects who had undergone colonoscopy and whose colonoscopic results were negative for malignancy or colorectal adenomas. They were sampled in the same time frame as the cases. All participants signed an informed written consent and the design of the study was approved by the Ethical Committee of the Institute of Experimental Medicine, Prague, Czech Republic. The second case-control study comprises 3662 participants, 1809 cases and 1853 controls recruited from the DACHS (Darmkrebs: Chancen der Verhütung durch Screening) study, [37]. Cases had incident invasive CRC diagnosed between January 2003 and March 2007. They were recruited from patients who received in-patient treatment in a hospital of the Rhein-Neckar-Odenwald region (Southwest Germany) due to a first diagnosis of CRC. Controls were frequency matched according to gender, county of residence and age and randomly selected from lists of population registries. The DACHS study was approved by the ethics committees of the Medical Faculty at the University of Heidelberg and of the Medical Chambers of Baden-Württemberg and Rhineland-Palatinate. All patients gave their informed written consent to participate in this study. In order to replicate the positive findings in the discovery set, we also used an independent population-based case-control study in a North German population that comprises 3803 subjects, 2169 cases and 1634 controls [38]. CRC cases were identified through the regional cancer registry of Schleswig-Holstein or through records of surgical departments in Northern Germany and recruited by the POPGEN biobank. Controls were randomly selected from population registries and also recruited by the POPGEN biobank. Additional controls were recruited from SHIP (Study of Health In Pomerania) in North-eastern Germany and were cancer-free at recruitment.

SNP Selection

The entire set of common genetic variants in ABCB1 was assessed following both tagging and functional approaches. The aim of the SNP tagging was to identify a set of SNPs that efficiently captures all the known common genetic variability, while the functional approach was used to determine the impact of potentially functional variants within ABCB1 gene on CRC risk. The tagging was carried out using the algorithm described by Carlson and co-workers [39]. All SNPs within the region of ABCB1 (including 5 kb upstream of the first exon and downstream of the last exon) and with a minor allele frequency (MAF) ≥5% in Caucasians (International HapMap Project, version 21a; http://www.hapmap.org), were included. Tagging SNPs were selected with the use of the Haploview Tagger program (http://www.broad.mit.edu/mpg/haploview/; http://www.broad.mit.edu/mpg/tagger/) [40], [41], using pairwise tagging with a minimum r2 of 0.8. This resulted in a selection of 28 tagging SNPs, with a mean r2 of the selected SNPs with the SNPs they tag of 0.976, meaning that our selection captures to a very high degree the known common variability in this gene. Considering that the genomic region of ABCB1 is characterized by high levels of linkage disequilibrium (LD), we postulate that such SNPs are also likely to tag any hitherto unidentified common SNPs in the gene. In order to test the hypothesis suggesting that functional SNPs rather than tagging SNPs might affect the ABCB1-mediated efflux of DNA damaging substances, we selected six potentially functional SNPs out of the 28 previously selected (rs2229109, rs1202168, rs1045642, rs9282564, rs2214102 and rs868755), and we genotyped them in the Czech and in the German DACHS populations. The selection was based on previously published results that pointed out either the functionality of ABCB1 variants [23], [42] or their association with various diseases [43], [44], [45]. In order to exhaustively cover all the genetic variability in the ABCB1 locus we have checked the variants described in the 1000 genome project and we found out that 180 SNPs have not been genotyped in in HapMap. We did not include these variants since in Caucasians the frequency of the minor allele was either missing or lower than the threshold of 0.05. Searching the database of genomic variants (http://projects.tcag.ca/variation/), which is a catalogue of structural variation in the human genome, we found that in Caucasian there is only a rare (MAF = 0.03%) copy number variant (CNV) and therefore we did not attempt to genotype it. Supplementary figure S1 shows in detail the number of SNPs and subjects genotyped in each phase. Supplementary figure S2 shows the LD plot of the ABCB1 gene, all the SNPs at the locus and the SNPs genotyped, while Supplementary table S1 shows the tagging SNPs selected in the study and the SNPs they tag.

DNA extraction and genotyping

For the Czech subjects DNA was extracted from blood using standard proteinase K digestion followed by phenol/chloroform extraction and ethanol precipitation. German DNA samples were isolated from peripheral blood mononuclear cells or mouthwash using Flexigene Kit 250 (Qiagen, Valencia, CA, USA) and Qiagen Mini Kit (Qiagen, Valencia, CA, USA), respectively. The order of DNAs from cases and controls was randomized on PCR plates in order to ensure that an equal number of cases and controls could be analyzed simultaneously. All the genotyping was carried out using Taqman (Applied Biosystems, Foster City, CA, USA) or KASPar (KBiosciences, Hoddesdon, Hertfordshire, UK) according to the manufacturers' protocols. Repeated quality control genotypes (8% of the total) showed an average concordance of 99.9%. More details on the genotyping methods can be found elsewhere [36], [46], [47]. PCR plates were read on an ABI PRISM 7900HT instrument (Applied Biosystems). The genotypes of SNPs rs2229109, rs1202168, rs1045642, rs9282564, rs2214102 partially overlap with those used in another project for a subset of the DACHS subjects reported here [48]. The results showed in the present paper have not been previously reported.

Statistical Analysis

Genotype distribution was examined in the cases and control populations. Hardy-Weinberg equilibrium was tested in the controls by chi square test and at the α = 1% level. We used logistic regression for multivariate analyses to assess the main effects of the genetic polymorphism on CRC risk using a log-additive inheritance model. The most common genotype in the controls was assigned as the reference category. All analyses were adjusted for age and gender. Additionally, we performed a logistic regression stratifying for the cancer site (colon versus rectum). All statistical analyses were performed using SAS 9.2. Since polymorphisms selected as tagging SNPs had a low level of residual linkage disequilibrium (LD), we assumed that haplotypes were adequately captured by our tagging SNP approach, and we did not attempt a haplotype analysis in the Czech population. However we performed it for the 6 SNPs selected as functional ones. Haplotype blocks were constructed from the control genotyping data using SNP-tool http://www.dkfz.de/de/molgen_epidemiology/tools/SNPtool.html, [49] and the algorithm implemented in Haploview based on confidence bounds by Gabriel and collegues [50]. The following cut-off values were used: MAF>5%, HWE p≥0.01 and 75% of non-missing genotypes. Maximum likelihood estimates of the haplotype frequencies were generated with an expectation-maximization based algorithm implemented in the PROC HAPLOTYPE procedure of SAS. Unconditional logistic regression adjusted for age (continuous), sex and study centre was used to calculate risk estimates. The most frequent haplotype was set as the reference, whereas haplotypes with a frequency below 0.05 were declared as rare haplotypes and combined. To evaluate the possibility of false positives, we took into account the issue of multiple testing. SNPSpD software (http://genepi.qimr.edu.au/general/daleN/SNPSpD), based on the use of the spectral decomposition (SpD) of matrices of pairwise LD between SNPs, was used to calculate the effective number of independent markers (Meff) for multiple testing [51], [52]. The p-values were evaluated in light of the Meff value.

Results

We performed a case-control study using three nested sets of ABCB1 SNPs in three distinct populations of Czech and German origins. The first SNP set consisted of 28 tagging SNPs, which we tested in 699 cases and 622 controls from the Czech Republic. The second SNP set consisted of a subgroup of the 28 tagging SNPs, namely six putatively functional SNPs, which we additionally typed in a German population of 1809 cases and 1853 controls. Finally, we replicated the best hits, namely SNPs rs1202168, rs1045642, rs9282564, and rs868755, in up to 2169 additional cases and 1634 additional controls from North Germany. These four SNPs were therefore typed in all the populations, giving this study a final sample size of up to 4677 cases and 4109 controls. The relevant characteristics of the three populations are reported in table 1. The genotype frequencies among the controls were in Hardy-Weinberg equilibrium for all the SNPs and in all populations. The calculated Meff value was 16. We therefore considered a study-wide significance p-value threshold of 0.05/16 = 0.003.
Table 1

Population characteristics.

Czech population CasesControls
(n = 699)(n = 622)
Males (%)*397 (56.8)336 (54.0)
Females (%)302 (43.2)286 (46.0)
Age (Age at Diagnosis)Median6256
Range27–9028–91
Mean (SD)61.1 (11.0)55.3 (13.5)
Rectal cancer (%)38.7
Colon cancer (%)61.3
DACHS population CasesControls
(n = 1809)(n = 1853)
Males (%)*1056 (58.4)1095 (59.1)
Females (%)753 (41.6)758 (40.9)
Age (Age at Diagnosis)Median6970
Range33–9434–98
Mean (SD)68.3 (10.4)68.6 (10.2)
Rectal cancer (%)39.0
Colon cancer (%)61.0
Kiel population CasesControl
(n = 2169)(n = 2060)
Males (%)*1087 (50.1)986 (47.9)
Females (%)1082 (49.9)1074 (52.1)
Age (Age at Diagnosis)Median6265
Range10–8523–81
Mean (SD)60.9 (8.8)64.7 (10.0)
Rectal cancer (%)51.4
Colon cancer (%)48.6

Results in the discovery set

The analysis of the 28 tagging SNPs in the Czech population did not reveal any statistically significant association (using the threshold of p = 0.003). The distribution of the genotypes of the 28 SNPs in the Czech population and their odds ratios (ORs) for association with CRC risk are shown in Supplementary Table S2. Associations of three polymorphisms with CRC risk at the conventional level of p<0.05 were observed in the DACHS study. Carriers of the rs1202168_T and rs868755_T alleles had an increased risk of CRC (ORhet = 1.20, 95%CI 1.04–1.40, ORhom = 1.23, 95%CI 1.01–1.48, P = 0.016, and ORhet = 1.17, 95%CI 1.00–1.36, ORhom = 1.22, 95%CI 1.01–1.48, P = 0.029, respectively) while individuals bearing the rs1045642_C allele had a decreased risk of CRC (ORhom = 0.79, 95%CI 0.66–0.96, P = 0.022, Supplementary Table S3).

Results of the replication study

Four SNPs which showed a statistically significant (rs1202168, rs1045642, rs868755) or borderline significant (rs9282564) association in the German discovery set were typed in an additional set of CRC cases and healthy controls from Germany. None of the SNPs showed a statistically significant association with CRC risk in the replication set or in the combined dataset. The distribution of the genotypes of the four SNPs typed in all the subjects of this study and their ORs for association with CRC risk are shown in Table 2.
Table 2

Replication of ABCB1 polymorphisms.

CZECHa populationDACHSa populationKIELa populationTotala populationCzech populationDACHS populationKIEL populationTotal population
ControlsCasesControlsCasesControlsCasesControlsCasesOR (95% CI)b p trendOR (95% CI)b p trendOR (95% CI)b p trendOR (95% CI)b p trend
rs868755
G/G20121556849834623911159521.000.8841.000.0291.000.4431.000.086
G/T227295794805521335154214351.22 (0.94–1.60)1.17 (1.00–1.36)0.81 (0.63–1.05)1.11 (0.99–1.25)
T/T92923443641621155985710.93 (0.65–1.34)1.22 (1.01–1.48)0.94 (0.67–1.32)1.12 (0.97–1.29)
rs1202168
C/C206231647568551726140415251.000.9121.000.0161.000.6141.000.263
C/T2743298358807951001190422101.11 (0.86–1.43)1.20 (1.04–1.40)0.96 (0.83–1.11)1.07 (0.98–1.18)
T/T1121183183412843577148160.94 (0.67–1.31)1.23 (1.01–1.48)0.96 (0.79–1.16)1.06 (0.93–1.20)
rs1045642
T/T1661904865013131929658831.000.7971.000.0221.000.0511.000.297
T/C279335868918510354165716071.04 (0.80–1.37)1.03 (0.88–1.20)1.14 (0.87–1.49)1.06 (0.95–1.19)
C/C1311424473672021507806590.95 (0.68–1.32)0.79 (0.66–0.96)1.39 (1.00–1.92)0.92 (0.80–1.05)
rs9282564
A/A4324641471141710041355290732361.000.7091.000.0521.000.7191.000.123
A/G1291363013412453696758461.03 (0.78–1.37)1.18 (1.00–1.41)1.12 (0.93–1.34)1.12 (1.00–1.26)
G/G10122124181349491.20 (0.51–2.83)1.20 (0.67–2.17)0.53 (0.26–1.09)0.92 (0.62–1.38)

Numbers may not add up to 100% of subjects due to genotyping failure.

Models were adjusted for age, sex and (in the combined population) study.

Numbers may not add up to 100% of subjects due to genotyping failure. Models were adjusted for age, sex and (in the combined population) study.

Haplotype analysis

None of the haplotypes showed a statistically significant association after correction for multiple testing. When testing the haplotypes in the pooled population, none showed any statistically significant association with CRC risk at the conventional threshold of P = 0.05. The distribution of ABCB1 haplotypes for the functional SNPs and risk of CRC are shown in supplementary table S4.

Discussion

Although functional data regarding ABCB1 SNPs are not totally consistent, some of them have reported to be involved with an enhanced efflux transporting ability [23], [42], [53]. Likewise, several of these functional polymorphisms have been found to be associated with CRC risk factors such as ulcerative colitis or obesity [54], [55], [56]. The present study attempted to evaluate systematically the role of common ABCB1 polymorphisms on CRC risk. Several studies have investigated the possible role of genetic variants in ABCB1 and risk of colorectal disease, mostly focusing on C3435T (rs1045642) and on 2677G>T/A (rs2032582). Overall these studies are heterogeneous in terms of size, number of SNPs tested, methodology used and ethnicity. C3435T was found to be associated with disease risk in several case-control studies [33], [57], [58], [59] while others did not find any statistically significant associations [34], [60] The polymorphism variant 2677G>T/A (rs2032582) in exon 21 has also been found associated with CRC risk [26], [45], [59], although not in all studies [34]. Anderson and colleagues also tested the possible association of rs3789243 in two distinct studies. They found an association in a Danish population but did not find anything in a study based on Norwegian subjects [3], [57]. In this study we have genotyped rs3789243 and we did not observe any statistically significant association. Three ABCB1 variants (rs1202168, rs1045642 and rs868755) were found to be associated with CRC risk in the DACHS study population. Carriers of the rs1202168_T and rs868755_T alleles showed an increased risk of CRC, while individuals bearing the, rs1045642_C allele (also referred to as C3435 in previous studies) showed a decreased risk for CRC. The results regarding rs1202168 and rs868755 are novel, although rs2032582 and rs868755 are in high LD (r2 = 0.85), while the results regarding rs1045642 are in concordance with several other studies that found that the C3435T polymorphism contribute to risk of CRC. In agreement with our results, Kurzawski and co-workers found that carriers of the variant allele of the C3435T polymorphism had an increased risk of CRC while carriers of CC genotype had the lowest risk for CRC [33]. In addition, several haplotypes containing the rs1045642_C allele have been associated with slower CRC progression [30]. Kimchi-Sarfaty and co-workers also suggested that this silent polymorphism affect the post-translational protein folding and its transport activities [61]. However, current data regarding the influence of ABCB1 SNPs on CRC risk are conflicting and, although three SNPs in the DACHS population showed a statistically significant association with CRC, none of them showed the same trend in the replication study. In addition, it is worth to note that our replication study performed in a Northern German population from Kiel showed that the rs1045642_C allele was associated with an increased, albeit not statistically significant, risk for CRC, i.e., an opposite effect to the one found in the DACHS study. These results obtained in the Northern Germans are in concordance with those previously published in a Danish population [57]. Consequently, it might be conceivable to think that the interplay between genetic variants and environmental factors could modify the risk of CRC. Genome-wide association studies (GWAS) of CRC have confirmed the hypothesis that part of the heritable risk for this disease is caused by common, low-risk variants and have identified various common variants associated with CRC risk [62], [63], [64], [65], [66] but none of the GWAS reported polymorphisms in the ABCB1 gene as major CRC risk factors. However, since only associations significant at the genome-wide level (typically p<10−7) are reported in GWAS it is not possible to exclude that ABCB1 polymorphisms were associated with CRC risk but were not reported due to the strict statistical threshold used. It has been indeed documented that GWAS are prone to reporting false negative results [67]. To our knowledge, the present study is one of the largest studies to address the potential association between ABCB1 polymorphisms and CRC risk. In this study we had a statistical power greater than 80% to detect an association for a log additive model with OR = 1.45 at α = 0.001 for the tagSNPs discovery set (MAF = 0.30), OR = 1.23 for the functional discovery set (MAF = 0.30) and OR = 1.16 for the joint analysis (MAF = 0.30). Moreover the hybrid tagging/functional approach facilitated a comprehensive analysis of common variants in the ABCB1 gene region in two well-defined and homogeneous study populations with a sufficient size. In addition, we used a large population-based study carried out in the same ethnic group for replication. Nonetheless, this study has some potential limitations. First, the large number of test performed could lead to chance finding and indeed, adding the correction for multiple testing none of the SNPs showed statistically significant associations. Moreover, even if the three populations are of Caucasian origin, a possible heterogeneity between them could still be present. Finally in this report we did not consider rare variants either as SNPs or CNVs. In conclusion in this report we cannot completely exclude a role, albeit minor, for ABCB1 gene variants and CRC risk. Shows in detail the number of SNPs and subjects genotyped in each phase. (PPT) Click here for additional data file. LD plot of the ABCB1 gene showing all the SNPs at the locus and the tagging selection. In the top left corner are shown the locus position and its size. The numbers in the diamonds are r2 values and the SNPs indicated with an * are the tagging SNPs selected for this study. (TIF) Click here for additional data file. Tagging SNPs selected in the study and the SNPs they tag. (DOC) Click here for additional data file. Distribution of ABCB1 polymorphisms and risk of CRC in the Czech population. (DOC) Click here for additional data file. Distribution of ABCB1 polymorphisms and risk of CRC in the German DACHS population. (DOC) Click here for additional data file. Distribution of ABCB1 haplotypes for the functional SNPs and risk of CRC. (XLS) Click here for additional data file.
  67 in total

1.  Association between two polymorphisms of ABCB1 and breast cancer risk in the current studies: a meta-analysis.

Authors:  Pei-Hua Lu; Mu-Xin Wei; Jie Yang; Xiao Liu; Guo-Qing Tao; Wei Shen; Min-Bin Chen
Journal:  Breast Cancer Res Treat       Date:  2010-07-13       Impact factor: 4.872

2.  Efficiency and power in genetic association studies.

Authors:  Paul I W de Bakker; Roman Yelensky; Itsik Pe'er; Stacey B Gabriel; Mark J Daly; David Altshuler
Journal:  Nat Genet       Date:  2005-10-23       Impact factor: 38.330

3.  Variation in the vitamin D receptor gene is not associated with risk of colorectal cancer in the Czech Republic.

Authors:  David J Hughes; Ivona Hlavatá; Pavel Soucek; Barbara Pardini; Alessio Naccarati; Ludmila Vodickova; Mazda Jenab; Pavel Vodicka
Journal:  J Gastrointest Cancer       Date:  2011-09

Review 4.  Genetic predisposition to colorectal cancer.

Authors:  Albert de la Chapelle
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

5.  ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.

Authors:  Sharon E Johnatty; Jonathan Beesley; Jim Paul; Sian Fereday; Amanda B Spurdle; Penelope M Webb; Karen Byth; Sharon Marsh; Howard McLeod; Paul R Harnett; Robert Brown; Anna DeFazio; Georgia Chenevix-Trench
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

Review 6.  Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence.

Authors:  Raphaëlle L Santarelli; Fabrice Pierre; Denis E Corpet
Journal:  Nutr Cancer       Date:  2008       Impact factor: 2.900

7.  Association of a polymorphism of ABCB1 with obesity in Japanese individuals.

Authors:  Sahoko Ichihara; Yoshiji Yamada; Kimihiko Kato; Takeshi Hibino; Kiyoshi Yokoi; Hitoshi Matsuo; Tai Kojima; Sachiro Watanabe; Norifumi Metoki; Hidemi Yoshida; Kei Satoh; Yukitoshi Aoyagi; Akitomo Yasunaga; Hyuntae Park; Masashi Tanaka; Yoshinori Nozawa
Journal:  Genomics       Date:  2008-04-28       Impact factor: 5.736

8.  Active transport of benzo[a]pyrene in apical membrane vesicles from normal human intestinal epithelium.

Authors:  J I Penny; F C Campbell
Journal:  Biochim Biophys Acta       Date:  1994-05-25

9.  ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer.

Authors:  Mariusz Panczyk; Ewa Balcerczak; Sylwester Piaskowski; Krzysztof Jamroziak; Grazyna Pasz-Walczak; Marek Mirowski
Journal:  Int J Colorectal Dis       Date:  2009-05-05       Impact factor: 2.571

10.  Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk.

Authors:  Emma Jaeger; Emily Webb; Kimberley Howarth; Luis Carvajal-Carmona; Andrew Rowan; Peter Broderick; Axel Walther; Sarah Spain; Alan Pittman; Zoe Kemp; Kate Sullivan; Karl Heinimann; Steven Lubbe; Enric Domingo; Ella Barclay; Lynn Martin; Maggie Gorman; Ian Chandler; Jayaram Vijayakrishnan; Wendy Wood; Elli Papaemmanuil; Steven Penegar; Mobshra Qureshi; Susan Farrington; Albert Tenesa; Jean-Baptiste Cazier; David Kerr; Richard Gray; Julian Peto; Malcolm Dunlop; Harry Campbell; Huw Thomas; Richard Houlston; Ian Tomlinson
Journal:  Nat Genet       Date:  2007-12-16       Impact factor: 38.330

View more
  14 in total

Review 1.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

2.  Association between the C3435T polymorphism of ABCB1/MDR1 gene (rs1045642) and colorectal cancer susceptibility : a meta-analysis based on 11,339 subjects.

Authors:  Li Zhao; Kai Li; Wusheng Li; Zhen Yang
Journal:  Tumour Biol       Date:  2013-03-16

3.  Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.

Authors:  Vibeke Andersen; Katrine Svenningsen; Lina Almind Knudsen; Axel Kornerup Hansen; Uffe Holmskov; Allan Stensballe; Ulla Vogel
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

4.  Colorectal cancer susceptibility: apparent gender-related modulation by ABCB1 gene polymorphisms.

Authors:  Marcella Martinelli; Luca Scapoli; Francesca Cura; Maria Teresa Rodia; Giampaolo Ugolini; Isacco Montroni; Rossella Solmi
Journal:  J Biomed Sci       Date:  2014-09-04       Impact factor: 8.410

5.  MDR1A deficiency restrains tumor growth in murine colitis-associated carcinogenesis.

Authors:  Eva Maria Hennenberg; Annette Eyking; Henning Reis; Elke Cario
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

6.  Association between polymorphisms of TAS2R16 and susceptibility to colorectal cancer.

Authors:  Jonathan Barontini; Marco Antinucci; Sergio Tofanelli; Maurizio Cammalleri; Massimo Dal Monte; Federica Gemignani; Pavel Vodicka; Roberto Marangoni; Ludmila Vodickova; Juozas Kupcinskas; Veronika Vymetalkova; Asta Forsti; Federico Canzian; Angelika Stein; Victor Moreno; Nicola Mastrodonato; Francesca Tavano; Anna Panza; Roberto Barale; Stefano Landi; Daniele Campa
Journal:  BMC Gastroenterol       Date:  2017-09-15       Impact factor: 3.067

7.  The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case-control studies.

Authors:  Ling-Hui Wang; Yan-Bin Song; Wen-Ling Zheng; Ling Jiang; Wen-Li Ma
Journal:  Cancer Cell Int       Date:  2013-05-20       Impact factor: 5.722

8.  Low ABCB1 gene expression is an early event in colorectal carcinogenesis.

Authors:  Vibeke Andersen; Ulla Vogel; Sine Godiksen; Franz B Frenzel; Mona Sæbø; Julian Hamfjord; Elin Kure; Lotte K Vogel
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

9.  Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer.

Authors:  Yan Du; Tong Su; Lijun Zhao; Xiaojie Tan; Wenjun Chang; Hongwei Zhang; Guangwen Cao
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

10.  Association between MDR1 polymorphisms and XELIRI and XELOX chemoresistance in Saudi patients with colorectal cancer.

Authors:  Ayat B Al-Ghafari; Areej M Al Qahtani; Suzan N Alturki; Huda A Al Doghaither; Ekramy M Elmorsy; Hanaa M Tashkandi; Atlal M Abusanad; Shadi S Alkhayyat; Ulfat M Omar; Ahmed A Zeeneldin
Journal:  Oncol Lett       Date:  2020-08-24       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.